Clinical trial
Safety and Immunogenicity Study of the New dHER2 Vaccine to Treat HER2-positive…
NCT00140738 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00140738 |
|---|---|
| Title | Safety and Immunogenicity Study of the New dHER2 Vaccine to Treat HER2-positive Metastatic Breast Cancer |
| Official title | A Multicenter, Open-label Phase I/II Trial of the Safety and Efficacy of the dHER2 Recombinant Protein Combined With Immunological Adjuvant AS15 in Patients With Metastatic Breast Cancer Overexpressing HER2/Neu |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Neoplasms, Breast |
| Intervention type | Biological |
| Interventions | GSK Biologicals' 719125 |
| Enrollment | 3 |
| Start date | Mar 10, 2005 |
| Primary completion | Sep 29, 2008 |
| Completion | Sep 29, 2009 |
| First posted | Sep 1, 2005 |
| Last update posted | Dec 27, 2019 |
| Countries | Belgium, Colombia, France, Italy, Peru |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: